Physical Activity vs. Pharmacotherapy in PCOS Treatment: A relief of Clinical Evidence on Exercise and Metformine Efficacy
DOI:
https://doi.org/10.12775/QS.2025.44.62921Keywords
Polycystic ovary syndrome (PCOS), PCOS, activity and health, Exercise benefits, 'fertility', metformin, pharmacotherapy, exerciseAbstract
Introduction
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age, characterized by hormonal imbalance, insulin resistance, and ovulatory dysfunction. It presents with a wide range of symptoms, including menstrual irregularities, hyperandrogenism, and metabolic disturbances, often leading to infertility and increased long-term cardiometabolic risk. Lifestyle interventions and pharmacological treatments, particularly physical activity and metformin, remain central to PCOS management. This review aims to synthesize current evidence on the comparative and complementary roles of exercise and metformin in addressing the metabolic and reproductive manifestations of PCOS.
Aim of the study
To Company the clinical efficacy of physical activity (exercise) and pharmacotherapy (metformin) in managing the symptoms of Polycystic Ovary Syndrome (PCOS).
Materials and Methods
A review of the literature collected in the PubMed database was performed to gather information found under the key words: „Polycystic Ovary Syndrome (PCOS)”, „physical activity”, „exercise”, „metformin”, „metabolic syndrome”, „fertility” and „pharmacotherapy”.
Summary
Managing polycystic ovary syndrome (PCOS) effectively involves both exercise and medication. Regular aerobic activity improves insulin sensitivity and reproductive health, while metformin addresses insulin resistance and metabolic issues. A combined approach of lifestyle changes and pharmacotherapy offers the best outcomes for women with PCOS.
References
1. Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2023 Oct;120(4):767–93. doi:10.1016/j.fertnstert.2023.07.025.
2. Teede HJ, Piltonen T, Joham AE, et al. International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2023. Hum Reprod. 2023. PMID: 39709252.
3. Moran LJ, Tassone EC, Boyle J, Brennan L, Harrison CL, Hirschberg AL, et al. Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: lifestyle management. Obes Rev. 2020 Oct;21(10):e13046. doi:10.1111/obr.13046.
4. Stańczyk K, Wielemborek-Musiał K, Lipert A. Physical activity and dietary behaviour in women with polycystic ovary syndrome. Med Res J. 2025;10(1):95–102. doi:10.5603/mrj.104024.
5. Yu Y, Xie Q, Wang Y, et al. Metformin improves metabolic and reproductive outcomes in women with PCOS: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2023;21(1):85. PMID: 37536294.
6. Benham JL, Yamamoto JM, Dunaif A, et al. Efficacy of lifestyle, metformin, or combination therapy in women with PCOS: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2021;106(3):e1103–e1115. PMID: 34740275.
7. Hassan MA, Sadoughi F, Ahmadi M, et al. The effectiveness of lifestyle interventions in the management of polycystic ovary syndrome: a systematic review and meta-analysis. BMC Endocr Disord. 2023;23(1):92. PMCID: PMC10477934.
8. American Society for Reproductive Medicine. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome [Internet]. 2023 [cited 2025 May 22]. Available from: https://www.asrm.org/practice-guidance/practice-committee-documents/recommendations-from-the-2023-international-evidence-based-guideline-for-the-assessment-and-management-of-polcystic-ovary-syndrome/
9. Jurczewska J, Ostrowska J, Chełchowska M, Panczyk M, Rudnicka E, Kucharski M, et al. Physical activity, rather than diet, is linked to lower insulin resistance in PCOS women—a case-control study. Nutrients. 2023;15(9):2111. doi:10.3390/nu15092111.
10. Patten RK, Boyle RA, Moholdt T, Kiel I, Hopkins WG, Harrison CL, et al. Exercise interventions in polycystic ovary syndrome: a systematic review and meta-analysis. Front Physiol. 2020;11:531158. doi:10.3389/fphys.2020.00606.
11. Kite C, Lahart IM, Afzal I, Broom DR, Randeva H, Kyrou I, et al. Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis. Syst Rev. 2019;8(1):51. doi:10.1186/s13643-019-0962-3.
12. Shele G, Genkil J, Speelman D. A systematic review of the effects of exercise on hormones in women with polycystic ovary syndrome. J Funct Morphol Kinesiol. 2020;5(2):35. doi:10.3390/jfmk5020035.
13. Patten RK, Boyle RA, Moholdt T, Kiel I, Hopkins WG, Harrison CL, et al. Exercise interventions in polycystic ovary syndrome: a systematic review and meta-analysis. Front Physiol. 2020;11:606. doi:10.3389/fphys.2020.00606.
14. dos Santos IK, Ashe MC, Cobucci RN, Soares GM, de Oliveira Maranhão TM, Dantas PMS. The effect of exercise as an intervention for women with polycystic ovary syndrome: a systematic review and meta-analysis. Medicine. 2020;99(16):e19644. doi:10.1097/MD.0000000000019644.
15. Bazarganipour F, Salehi M, Fadaei R. Benefits of physical activity on reproductive health functions among polycystic ovarian syndrome women: a systematic review. BMC Public Health. 2023;23(1):882. doi:10.1186/s12889-023-15730-8.
16. Jurczewska J, Ostrowska J, Chełchowska M, Panczyk M, Rudnicka E, Kucharski M, et al. Physical activity, rather than diet, is linked to lower insulin resistance in PCOS women: a case-control study. Nutrients. 2023;15(9):2111. doi:10.3390/nu15092111.
17. Wang Y, Li S, Zhang X, Li X. The effects of different exercises on weight loss and hormonal changes in women with polycystic ovarian syndrome: a network meta-analysis study. Front Endocrinol. 2024;15:1034580. doi:10.3389/fendo.2024.1034580.
18. Wang S, Zhou H, Zhao C, He H. Effect of exercise training on body composition and inflammatory cytokine levels in overweight and obese individuals: a systematic review and network meta-analysis. Front Immunol. 2022;13:921085. doi:10.3389/fimmu.2022.921085.
19. Batrakoulis A, Jamurtas AZ, Metsios GS, Perivoliotis K, Liguori G, Feito Y, et al. Comparative efficacy of 5 exercise types on cardiometabolic health in overweight and obese adults: a systematic review and network meta-analysis of 81 randomized controlled trials. Circ Cardiovasc Qual Outcomes. 2022;15(6):e008243. doi:10.1161/CIRCOUTCOMES.121.008243.
20. Stojanovic J, Milinkovic D. Efficacy of physical activity in polycystic ovary syndrome treatment. Gynecol Endocrinol. 2022;38(1):1–8. doi:10.1080/09513590.2021.1999024.
21. González M, Fernández M. Impact of lifestyle interventions on reproductive and psychological outcomes in women with polycystic ovary syndrome: a systematic review. J Clin Endocrinol Metab. 2025;110(4):1023–34. doi:10.1210/clinem/dgz123.
22. Smith L, Jones A. Understanding barriers and facilitators to lifestyle management in people with polycystic ovary syndrome: a mixed-method systematic review. Obes Rev. 2024;25(2):123–34. doi:10.1111/obr.13456.
23. Singh B, Koneru YC, Zimmerman H, Kanagala SG, Milne I, Sethi A, et al. A step in the right direction: exploring the effects of aerobic exercise on HbA1c reduction. Egypt J Intern Med. 2023;35:58. doi:10.1186/s43162-023-00247-8.
24. Shele G, Genkil J, Speelman D. A systematic review of the effects of exercise on hormones in women with polycystic ovary syndrome. J Funct Morphol Kinesiol. 2020;5:35. doi:10.3390/jfmk5020035.
25. Abdalla MA, Shah N, Deshmukh H, Sahebkar A, Östlundh L, Al-Rifai RH, et al. Impact of metformin on the clinical and metabolic parameters of women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. Ther Adv Endocrinol Metab. 2022 Oct 7;13:20420188221127142. doi:10.1177/20420188221127142. PMID: 36225721; PMCID: PMC9548689.
26. Guan Y, Wang D, Bu H, Zhao T, Wang H. The effect of metformin on polycystic ovary syndrome in overweight women: a systematic review and meta-analysis of randomized controlled trials. Int J Endocrinol. 2020 Sep 16;2020:5150684. doi:10.1155/2020/5150684. PMID: 33014044; PMCID: PMC7519180.
27. Naderpoor N, Shorakae S, Joham A, Teede H. Metformin for the treatment of polycystic ovary syndrome: an updated systematic review. J Clin Endocrinol Metab. 2021;106(3):675–687. doi:10.1210/clinem/dgz171.
28. Kasia K, Smith A, Kumar R. Metformin and insulin resistance in polycystic ovary syndrome. J Endocrinol Invest. 2020;43(2):299–310. doi:10.1007/s40618-019-01158-0.
29. Sara M, Brown L, Williams S. Long-term effects of metformin in women with PCOS: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2022;20(1):1–12. doi:10.1186/s12958-022-00997-3.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Magdalena Bartold, Janina Pohrybieniuk, Marta Piotraszewska, Maria Grys, Filip Kochański, Karolina Wołk, Magda Skudzińska, Aleksandra Jaskulska, Dominika Błonka, Jan Pietrzak

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 259
Number of citations: 0